Efficacy and Safety Study of Aplindore in Patients With Restless Legs Syndrome

PHASE2TerminatedINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

November 30, 2009

Study Completion Date

December 31, 2009

Conditions
Restless Legs Syndrome
Interventions
DRUG

aplindore MR tablets or Placebo

aplindore MR tablets administered QD for about 4 weeks

Trial Locations (24)

27612

Wake Research Associates, Raleigh

29464

Coastal Carolina Research Center, Mt. Pleasant

30342

Neurotrials Research, Inc., Atlanta

32720

University Clinical Research Deland, LLC, DeLand

33009

MD Clinical, Hallandale

33013

Miami Research Associates, South Miami

33024

University Clinical Research, Pembroke Pines

33026

Broward Research Group, Pembroke Pines

33761

Tampa Bay Medical Research, Clearwater

41017

Community Research & Sleep Management Institute, Crestview Hills

44130

North Star Medical Research, LLC, Middleburg Heights

45227

Comunity Reasearch, Cincinnati

45246

Tri-State Sleep Disorders Center, Cincinnati

48025

Quest Research Institute, Bingham Farms

60061

Sleep & Behavior Medicine Institute, Vernon Hills

63017

Sleep Medicine and Research Center - St Luke's Hospital, Chesterfield

73112

Lynn Health Science Institute, Oklahoma City

75231

Sleep Medicine Associates of Texas, P.A., Dallas

78229

Paragon Research Center, San Antonio

81001

Lynn Institute of Pueblo, Pueblo

85050

HOPE Research Institute, Phoenix

85741

Genova Clinical Research, Tuscon

92056

Excell Research, Inc., Oceanside

06492

Gaylord Sleep Medicine, Wallingford

Sponsors
All Listed Sponsors
lead

Neurogen Corporation

INDUSTRY